LSA
LGND icon

L & S Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

L & S Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-14,993
Closed -$350K – 91
2013
Q2 		$350K Buy
+14,993
New +$270K 0.17% 60

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

L & S Advisors's LGND Position: Q3 2013 in Review

L & S Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2013, closing a stake of 14,993 shares — an estimated $350K sold.

L & S Advisors first reported a position in LGND in Q2 2013 and held it in 1 quarter. The position peaked at $350K in Q2 2013. 132 funds tracked by Wall St. Rank hold LGND as of Q3 2013.

  • L & S Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • L & S Advisors sold 14,993 Ligand Pharmaceuticals shares in Q3 2013, an estimated $350K.
  • L & S Advisors first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • L & S Advisors's Ligand Pharmaceuticals position peaked at $350K in Q2 2013.
  • 132 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2013.

Based on L & S Advisors's 13F filing for Q3 2013, filed 12 Nov 2013.